ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-15

Price

$115.00

+0.10%

Score17.5Priority

Signals6/8 DNA2/13 Act · 1/4 Risk

SentimentNEUTRALScore: 5

Volume0.5xvs 20d avg

Analysis

The price action of Arcellx is completely anchored by Gilead Sciences' pending $7.8 billion acquisition offer of $115 in cash plus a $5 Contingent Value Right (CVR). This definitive M&A agreement perfectly explains the stock's exceptionally low 1.9% realized volatility and the QUIET_STORM signal, as institutional merger arbitrageurs pin the price precisely at the $115.00 cash consideration. Furthermore, the RISK_ON macro regime, highlighted by exceptionally tight high-yield credit spreads (0.81%), provides supreme conviction that Gilead faces zero financing hurdles, virtually guaranteeing a smooth path to the expected Q2 2026 close.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEINSIDE OUTWEAK FINISH

Key Takeaways

M&A PIN: ACLX is trading exactly at Gilead's base cash offer of $115.00, rendering traditional technical momentum signals secondary to merger arbitrage [1.1].
CVR UPSIDE: The only remaining structural upside is tied to the $5 per share Contingent Value Right, which depends on specific post-merger milestones.
DEAL CLOSURE: With M&A financing risks neutralized by a strong credit market, focus shifts entirely to final regulatory approvals and the imminent Q2 2026 close.

← Back to 2026-04-15 View Full ACLX History →Yahoo Finance &nearr;